[ 46 ] noted that higher BMI, particularly in obese patients (BMI ≥ 25 kg/m 2 ), was associated with a 25% lower risk of disease progression (HR = 0.75; 95% CI: 0.62–0.92), with a significant trend of decreasing progression risk with increasing BMI.
← all excerpts
The Impact of Body Composition on Outcomes in NSCLC Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review.
2
—
—
The sentences
[ 48 ] observed shorter PFS and OS in cachectic patients, but these differences did not reach statistical significance.